OBJECTIVES: To estimate and stratify the risk of development of nephrogenic systemic fibrosis (NSF) in well-defined at-risk subpopulations from a large single institution, and to perform a single-institution case series study of patients with biopsy-proven NSF. DESIGN: Retrospective cohort of patients exposed to gadolinium-based contrast agents (GBCAs) at a single institution during an 8-year period (January 1, 1999, to December 31, 2006), and a case series study of patients with biopsy-proven NSF. SETTING: A primary, secondary, and tertiary health care center that treated more than 2.2 million outpatients and had 135 000 hospital admissions in 2007. Patients A total of 94 917 patients exposed to GBCAs; patients at risk for NSF (3779 patients on hemodialysis, 1694 patients with renal transplants, and 717 patients with liver transplants, a well-defined subgroup that includes patients at risk for reduced renal function); and 61 patients with a clinical diagnosis of NSF. MAIN OUTCOME MEASURE: Risk estimate for NSF. RESULTS: The risk of development of NSF is 1.0% for patients who undergo hemodialysis (8 of 827), 0.8% for patients with renal transplantation (4 of 527), and 0% for patients with liver transplantation at our institution (0 of 327). CONCLUSIONS: Despite the limitations, this study, which reviewed a large number of patients who underwent intravascular GBCA injections, demonstrates a 77-fold higher risk of NSF among patients who undergo hemodialysis and a 69-fold higher risk in patients with renal transplantation. This increased risk is thought to be associated with poor clearance of most GBCAs.
OBJECTIVES: To estimate and stratify the risk of development of nephrogenic systemic fibrosis (NSF) in well-defined at-risk subpopulations from a large single institution, and to perform a single-institution case series study of patients with biopsy-proven NSF. DESIGN: Retrospective cohort of patients exposed to gadolinium-based contrast agents (GBCAs) at a single institution during an 8-year period (January 1, 1999, to December 31, 2006), and a case series study of patients with biopsy-proven NSF. SETTING: A primary, secondary, and tertiary health care center that treated more than 2.2 million outpatients and had 135 000 hospital admissions in 2007. Patients A total of 94 917 patients exposed to GBCAs; patients at risk for NSF (3779 patients on hemodialysis, 1694 patients with renal transplants, and 717 patients with liver transplants, a well-defined subgroup that includes patients at risk for reduced renal function); and 61 patients with a clinical diagnosis of NSF. MAIN OUTCOME MEASURE: Risk estimate for NSF. RESULTS: The risk of development of NSF is 1.0% for patients who undergo hemodialysis (8 of 827), 0.8% for patients with renal transplantation (4 of 527), and 0% for patients with liver transplantation at our institution (0 of 327). CONCLUSIONS: Despite the limitations, this study, which reviewed a large number of patients who underwent intravascular GBCA injections, demonstrates a 77-fold higher risk of NSF among patients who undergo hemodialysis and a 69-fold higher risk in patients with renal transplantation. This increased risk is thought to be associated with poor clearance of most GBCAs.
Authors: Colleen M Costelloe; William A Murphy; Tamara M Haygood; Rajendra Kumar; Kevin W McEnery; R Jason Stafford; Anjali Roy; Roland L Bassett; Robyn K Harrell; John E Madewell Journal: Skeletal Radiol Date: 2010-09-24 Impact factor: 2.199
Authors: Jeremías Bayón; María Martín; José Manuel García-Ruíz; Carmen Rodríguez Journal: Int J Cardiovasc Imaging Date: 2010-05-04 Impact factor: 2.357
Authors: B J Edwards; A E Laumann; B Nardone; F H Miller; J Restaino; D W Raisch; J M McKoy; J A Hammel; K Bhatt; K Bauer; A T Samaras; M J Fisher; C Bull; E Saddleton; S M Belknap; H S Thomsen; E Kanal; S E Cowper; A K Abu Alfa; D P West Journal: Br J Radiol Date: 2014-10 Impact factor: 3.039
Authors: Emmanuil Smorodinsky; David S Ansdell; Zeke W Foster; Sameer M Mazhar; Irene Cruite; Tanya Wolfson; Sebastian B Sugay; Gabriella Iussich; Masoud Shiehmorteza; Yuko Kono; Alexander Kuo; Claude B Sirlin Journal: J Magn Reson Imaging Date: 2014-05-09 Impact factor: 4.813
Authors: Nicola Schieda; Jason I Blaichman; Andreu F Costa; Rafael Glikstein; Casey Hurrell; Matthew James; Pejman Jabehdar Maralani; Wael Shabana; An Tang; Anne Tsampalieros; Christian B van der Pol; Swapnil Hiremath Journal: Can J Kidney Health Dis Date: 2018-06-12
Authors: Nasir Hussain; Paul Eric Shattuck; Mourad Hussein Senussi; Erwin Velasquez Kho; Mubeenkhan Mohammedabdul; Devang K Sanghavi; Usman Mustafa; Arvind Balavenkataraman; Dragic M Obradovic Journal: Case Rep Med Date: 2012-11-06
Authors: Tina R Elmholdt; Anne B B Olesen; Bettina Jørgensen; Stinne Kvist; Lone Skov; Henrik S Thomsen; Peter Marckmann; Michael Pedersen Journal: PLoS One Date: 2013-12-09 Impact factor: 3.240